Axon Therapies key facts
as of Oct 2026- Developer of a healthcare device designed to reduce sympathetic nerve activity and address the root cause of heart failure.
- Axon Therapies is valued at approximately $44.5M as of Oct 2026, set at its later-stage round, Jan 2021; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $75.8M across 3 recorded rounds; the latest was Early Stage VC ($7.5M) in Jan 2019.
- Notable investors include Earlybird Venture Capital, Deerfield Management, CDBI Partners, Action Potential Venture Capital, Coridea — 7 tracked in total.
- Axon Therapies has filed 4 Form Ds with the SEC since 2016, most recently Feb 2019 ($7.5M sold to 10 investors).
- Status: Privately Held (backing).
Valued at $44.5M at its later-stage round, Jan 2021. Nothing has traded since.
- ·Watch Axon Therapies: the Monday email on marks, rounds and moves
Axon Therapies funding rounds
3 roundsAxon Therapies valuation
Axon Therapies was valued at $44.5 million at its later-stage round in Jan 2021. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Axon Therapies raised?
Axon Therapies has raised $75.8 million in total; 3 of its rounds are on record, from 2016 on. The largest on record was a $7.5 million early-stage round in Jan 2019.
Axon Therapies has filed 4 Form Ds with the SEC since 2016, most recently in Feb 2019 ($7.5 million sold to 10 investors).
Axon Therapies investors
7 investors are on record for Axon Therapies, including Earlybird Venture Capital, Deerfield Management, CDBI Partners and Action Potential Venture Capital. The early-stage round in Jan 2019 drew 10 investors.
About Axon Therapies
Developer of a healthcare device designed to reduce sympathetic nerve activity and address the root cause of heart failure. The company's device allows clinicians to ablate the right greater splanchnic nerve using a small catheter inserted through the groin and helps to normalize sympathetic nervous activity, to shift blood volume from the heart back to the splanchnic bed, reducing pressures in the heart, enabling clinicians to begin treatment quickly, resulting in a high likelihood of successful treatment.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2014
- Employees
- 20
- Website
- axontherapies.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.